mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients
Por:
Albiol, N, Barata, A, Aso, O, Gomez-Perez, L, Triquell, M, Roch, N, Lazaro, E, Esquirol, A, Gonzalez, I, Lopez-Contreras, J, Sierra, J, Martino, R, Garcia-Cadenas, I
Publicada:
1 dic 2022
Ahead of Print:
1 sep 2022
Resumen:
Purpose This study aims to describe the incidence and severity of adverse events (AEs) following the mRNA-1273 SARS-CoV-2 vaccine and explore the risk perception of COVID-19 in allogeneic hematopoietic stem cell transplant (HCT) recipients. Methods We performed a single-center prospective study including recently transplanted (< 2 years post-infusion) allogeneic HCT recipients. AEs were assessed through phone calls and graded from 0 to 4, while COVID-19 risk perception was measured using the Brief Illness Perception Questionnaire (BIP-Q5). Results Fifty-four HCT recipients were evaluated. Incidence and grades of AE (94.4% and 85.2% after the first and second dose, respectively) were similar to those described in the general population. The most common AE was pain at the site of injection. Three patients (5.6%) developed a grade >= 3 AE. Vaccine-related cytopenias and graft-versus-host disease flares were not observed. Female sex (OR 3.94, 95% CI 1.14-13.58, p = 0.03) and time since HCT (per month since HCT: OR 1.09, 95% CI 1.01-1.18, p = 0.04) were associated with the occurrence of any AE. The patients' risk perception level of COVID-19 decreased over time (p < 0.05). Conclusion Our study confirms that the mRNA-1273 SARS-CoV-2 vaccine is safe in recent HCT recipients and suggests that the perceived risk of COVID-19 decreases over time.
Filiaciones:
Albiol, N:
Hosp La Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Inst Invest Biomed IIB St Pau, Barcelona, Spain
Autonomous Univ Barcelona, Barcelona, Spain
Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Barata, A:
H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL USA
Aso, O:
Hosp La Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Gomez-Perez, L:
Hosp La Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Triquell, M:
Hosp La Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Roch, N:
H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL USA
Lazaro, E:
Hosp La Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Esquirol, A:
Hosp La Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Inst Invest Biomed IIB St Pau, Barcelona, Spain
Autonomous Univ Barcelona, Barcelona, Spain
Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Gonzalez, I:
Hosp La Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Lopez-Contreras, J:
Autonomous Univ Barcelona, Barcelona, Spain
Hosp La Santa Creu & St Pau, Infect Dis Dept, Barcelona, Spain
Sierra, J:
Hosp La Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Inst Invest Biomed IIB St Pau, Barcelona, Spain
Autonomous Univ Barcelona, Barcelona, Spain
Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Martino, R:
Hosp La Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Inst Invest Biomed IIB St Pau, Barcelona, Spain
Autonomous Univ Barcelona, Barcelona, Spain
Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Garcia-Cadenas, I:
Hosp La Santa Creu & St Pau, Hematol Dept, Barcelona, Spain
Inst Invest Biomed IIB St Pau, Barcelona, Spain
Autonomous Univ Barcelona, Barcelona, Spain
Josep Carreras Leukaemia Res Inst, Barcelona, Spain
Green Published, Bronze, Green
|